Silo Pharma, Inc. filed a Form S-3 registration statement with the U.S. Securities and Exchange Commission on November 18, 2026, to register 566,666 shares of common stock for resale by selling shareholders in connection with a November 2026 private placement.
Key Highlights
- 566,666 total shares registered for resale on behalf of selling shareholders, according to the filing.
- 136,005 common shares were issued directly under a securities purchase agreement dated November 5, 2026, with accredited investors.
- 430,661 pre-funded warrant shares are issuable upon exercise of pre-funded warrants at an exercise price of $0.0001 per share.
- Gross proceeds of approximately $43 would be received by the company if all pre-funded warrants are exercised in cash, the filing stated.
- Closing price on November 17, 2026 was $1.71 per share on The Nasdaq Capital Market, as reported in the filing.
- Company will not receive proceeds from the resale of shares by selling shareholders, the filing disclosed.
Silo Pharma S-3 Registration: November 2026 Private Placement Details
Silo Pharma, Inc. (NASDAQ:SILO), a Nevada-incorporated company headquartered in Sarasota, Florida, filed a preliminary Form S-3 registration statement on November 18, 2026, covering the resale of 566,666 shares of common stock, par value $0.0001 per share. According to the filing, the shares consist of two components tied to a securities purchase agreement entered into with certain accredited investors on November 5, 2026.
The filing disclosed that 136,005 shares represent common stock issued directly under the purchase agreement, while the remaining 430,661 shares are issuable upon exercise of pre-funded warrants. The pre-funded warrants carry an exercise price of $0.0001 per share and are described as "immediately exercisable until such Pre-Funded Warrants are exercised in full." The company noted that if all pre-funded warrants are exercised for cash, gross proceeds to Silo Pharma would total approximately $43, though the filing cautioned that the company "cannot predict when and in what amounts or if the Warrants will be exercised by payments of cash." The common shares and pre-funded warrants were issued in private placement offerings pursuant to Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D.
The registration statement specifies that the selling shareholders may sell shares "through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices." The company stated it will not receive any proceeds from the resale of shares by the selling shareholders. The filing also noted there is no established public trading market for the pre-funded warrants and that Silo Pharma does not intend to list them on any national securities exchange. The company identified itself as a non-accelerated filer and a smaller reporting company.
What Was Disclosed
Silo Pharma filed an S-3 registration statement to register 566,666 shares for resale by selling shareholders, comprising 136,005 directly issued common shares and 430,661 pre-funded warrant shares, all stemming from a November 5, 2026 private placement with accredited investors.



Please wait processing your request...